Pfizer's Neurontin Marketing Hurt Payors, 1st Circ. Hears

Law360, New York (September 18, 2012, 8:46 PM EDT) -- Blue Cross Blue Shield of Louisiana and other third-party payors struck back at Pfizer Inc. on Tuesday in their bid to return their case to multidistrict litigation over alleged off-label marketing of epilepsy drug Neurontin, telling the First Circuit they had enough evidence to prove their claims of direct injury.

The brief, filed by several health plans and other third-party payors that provide medical and prescription drug coverage, takes issue with Pfizer's argument in the suit, which was dismissed in December 2010 from multidistrict litigation against...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.